Physician profile
Jeff Whitfield
NPI 1780662221
$481.12
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $54.62 · 2021: $50.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogpo LLC | $198.00 | 2019 | |
| Becton, Dickinson and Company | $50.23 | 2021 | |
| Axonics, INC. | $40.20 | 2020 | |
| Astellas Pharma US INC | $39.33 | 2019 | |
| Ferring Pharmaceuticals INC. | $31.81 | 2019 | |
| Amgen INC. | $23.60 | 2019 | |
| Dendreon Pharmaceuticals LLC | $20.89 | 2019 | |
| Abbvie INC. | $19.96 | 2019 | |
| Therapeuticsmd, INC. | $18.01 | 2019 | |
| Endo Pharmaceuticals INC. | $14.42 | 2020 | |
| Janssen Biotech, INC. | $12.85 | 2019 | |
| Allergan, INC. | $11.82 | 2019 |
Research and ownership
$68,225.49 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Whitfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.